Evidence map›Paper›PMID 40529304›Full record

ReviewFrontiers in cellular and infection microbiology2025

Microbiota and gastric cancer: from molecular mechanisms to therapeutic strategies.

Zhou Chen, Dacheng Jin, Jinjing Hu, Defeng Guan, Qizhou Bai, Yunjiu Gou

Abstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Advances inOncology letters · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Gut Microbiota-Driven Pathways Linking Chronic Stress to Tumor Progression.International journal of biological sciences · 2026
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhou ChenDepartment of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, Gansu, China.
Dacheng JinDepartment of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, Gansu, China.
Jinjing HuDepartment of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, Gansu, China.
Defeng GuanThe First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
Qizhou BaiDepartment of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, Gansu, China.
Yunjiu GouDepartment of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer, a prevalent malignancy globally, is influenced by various factors. The imbalance in the gut microbiome and the existence of particular intratumoural microbiota could have a strong connection with the onset and progression of gastric cancer. High-throughput sequencing technology and bioinformatics analysis have revealed a close correlation between abnormal abundance of specific microbial communities and the risk of gastric cancer. These microbial communities contribute to gastric cancer progression through mechanisms including increasing cellular genomic damage, inhibiting DNA repair, activating abnormal signaling pathways, exacerbating tumor hypoxia, and shaping a tumor immune-suppressive microenvironment. This significantly impacts the efficacy of gastric cancer treatments, including chemotherapy and immunotherapy. Probiotic, prebiotic, antibiotic, carrier-based, dietary interventions, fecal microbiota transplantation, and traditional Chinese medicine show potential applications in gastric cancer treatment. However, the molecular mechanisms regarding dysbiosis of microbiota, including gut microbiota, and intra-tumoral microbiota during the progression of gastric cancer, as well as the therapeutic efficacy of microbiota-related applications, still require extensive exploration through experiments.

Indexed as

Gastrointestinal MicrobiomeStomach NeoplasmsDysbiosisFecal Microbiota TransplantationHumansProbioticsTumor Microenvironmentgastric cancermicrobiotamolecular mechanismstargeted therapytumor microenvironment

Identifiers

PMID40529304
PMCPMC12170596

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.